Skip to content

PainDETECT-Questionnaire and DN4: A Dutch validation study in patients with low back pain, neck shoulder pain or with a neuropathic pain syndrome

PainDETECT-Questionnaire and DN4: A Dutch validation study in patients with low back pain, neck shoulder pain or with a neuropathic pain syndrome - Validation of the PDQ & DN4

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON33911
Enrollment
438
Registered
2009-02-23
Start date
2009-10-09
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nerve pain

Interventions

None listed

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Men & Women; at least 18 years old More than 3 months pain complaints as decripted above Pain Intensity Score > 3 (NRS)

Exclusion criteria

Exclusion criteria: patients with multiple painsyndromes Pain with an oncologic cause severe psychiatric disorder Abuse of alcohol and drugs Problems to understand the Dutch language

Design outcomes

Primary

MeasureTime frame
1. Outcome of the gold standard: The clinical examination serves as the goldstandard. Based on the grading system of Treede et al (2008), The gold standard is based on a standardized assessment performed by two independant working physicians. 2. Outcome of PDQ & DN4. 3. Outcome of Quantitative Sensory testing (QST): The German Research Network for Neuropathic Pain QST (GRNNP QST) protocol will be used (Rolke et al. 2006;Rolke et al. 2006).

Secondary

MeasureTime frame
1. Medical comorbidity: Questionnaire with the most prevalent and relevant medical 2. Mental health status: Hospital Anxiety Depression Scale (HADS) (Spinhoven et al. 1997). 3. Functioning: Disability Rating Index (DRI) (Salen et al. 1994). 4. Health related quality of life: Short form-36 (SF-36). 5. Pain Attribution Scale(Kraaimaat 200?). 6. prevalence of neuropathic pain in this patient groups.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)